Compare SSNC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSNC | BBIO |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 15.3B |
| IPO Year | 2007 | 2019 |
| Metric | SSNC | BBIO |
|---|---|---|
| Price | $75.29 | $65.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 23 |
| Target Price | ★ $101.00 | $82.26 |
| AVG Volume (30 Days) | 2.7M | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ 3.15 | N/A |
| Revenue | ★ $1,675,295,000.00 | $502,076,000.00 |
| Revenue This Year | $9.24 | $85.55 |
| Revenue Next Year | $5.04 | $71.10 |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | 13.09 | ★ 126.26 |
| 52 Week Low | $69.00 | $28.33 |
| 52 Week High | $91.07 | $84.94 |
| Indicator | SSNC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 36.67 |
| Support Level | $70.44 | $61.54 |
| Resistance Level | $86.59 | $68.71 |
| Average True Range (ATR) | 2.19 | 3.91 |
| MACD | 0.62 | -0.72 |
| Stochastic Oscillator | 77.20 | 11.61 |
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. Acquisitions are a large part of SS&C's history. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.